Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ustekinumab and CNTO 1959 in active rheumatoid arthritis despite methotrexate
2011-001122-18Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Ustekinumab plus methotrexate, CNTO 1959 plus methotrexate and Placebo plus methotrexate (3 arms). Primary endpoint: ACR20 response at Week 28. Started May 2012; status: completed.
02
Drugs
ustekinumabguselkumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-001122-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001122-18.